EFPIA and Vaccines Europe urge the avoidance of any reactionary measures that could disrupt the production and delivery of COVID-19 vaccines.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) and Vaccines Europe have stressed the need for the European Council to avoid any reactionary measures that could disrupt the production and delivery of COVID-19 vaccines.
European Union (EU) leaders are meeting via video conference on March 25–26, 2021 to discuss the COVID-19 epidemiological situation, among other items. EFPIA and Vaccines Europe have emphasized that any potential proposals to restrict exports by the commission at the meeting could lead to retaliations from other regions.
Owing to the nature of biological product manufacture, including vaccines, a global supply and effort is needed to source all the required component parts and materials. If export restrictions are put in place by the EU, it could lead to essential materials being prevented from importation into the region and, hence, placing EU citizens at risk due to a lack of available vaccines.
“Just one year on from the [World Health Organization] declaring COVID-19 a global pandemic, four vaccines have been approved for use by the [European Medicines Agency], 69.5 million doses distributed to EU/EAA countries and over 55 million doses administered to citizens across Europe. This is an incredible collaborative, scientific, manufacturing, and logistical achievement involving the EU institutions, governments, health-systems, regulators, and the research-based pharmaceutical industry. To take any measure that could be perceived as ‘vaccine nationalism’ at this critical moment would put this remarkable progress in severe jeopardy,” it was reported in a March 23, 2021 press release from EFPIA.
Source: EFPIA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.